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Background: To retrospectively analyze whether primary tumor volume and primary nodal volume could be
considered independent prognostic factors for nasopharyngeal carcinoma treated with intensity-modulated
radiation therapy.
Methods: Three hundred sixty-three consecutive nasopharyngeal carcinoma (NPC) patients who were stage I-IVa+b
and treated with intensity-modulated radiotherapy (IMRT) in our center from October 2003 to October 2005 were
analyzed retrospectively. The predictive ability of gender, age, T and N stage, combined chemotherapy, primary
tumor and nodal volume for the 5-year local control (LC), distant-metastasis free survival (DMFS) and overall survival
(OS) rate were investigated. Primary tumor and nodal volume were measured based on registration of magnetic
resonance imaging (MRI) with contrast-enhanced computed tomography (CT) images. The Kaplan–Meier method
was used for survival analysis, the log-rank test was used for univariate analyses and the Cox proportional hazard
model was used for multivariate prognostic analyses.
Results: The mean value of primary tumor and nodal volume were 31.5 ml and 9.7 ml. The primary tumor and
nodal volume were respectively divided into four groups for analysis (primary tumor volume: TV1≤20 ml,
20<TV2≤30 ml, 30<TV3≤40 ml, TV4>40 ml; primay nodal volume: NV1≤5 ml, 5<NV2≤10 ml, 10<NV3≤20 ml,
NV4>20 ml). In univariate analysis, the 5-year LC and DMFS rate for TV4 was significantly decreased compared to
the other groups (LC: p<0.001, DMFS: p=0.001), the 5-year OS rate for TV3 and TV4 were significantly decreased
compared to other two subgroups (p=0.002) and the 5-year regional control (RC), DMFS and OS rate for NV3 and
NV4 were significantly less than NV1 and NV2 (RC: p=0.002, DMFS: p=0.01, OS: p=0.014). Multivariate analysis
showed that TV>40 ml was an adverse prognostic factor for the 5-year local regional control (LRC) rate (RR 2.454,
p=0.002). Primary nodal volume had no statistical significance in predicting 5-year LRC, DMFS and OS rate in
multivariate analysis.
Conclusions: Primary tumor volume could predict LRC rate of NPC patients, and the primary tumor volume of 40 ml
may be the cut-off. Primary nodal volume may have predictive significance, but more data are needed. These factors
should be considered in the TNM staging system of NPC for better estimates of prognosis.
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Table 1 Clinical characteristic of 363 NPC patients
Characteristics N (%)
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NPC is a cancer of the nasopharyngeal cavity that has a
dramatic geographic and ethnic distribution. In some
areas of China, the incidence is as high as 30/100,000. It
is estimated that there are more than 50,000 newly diag-
nosed cases in China and 65,000 worldwide each year
[1]. Radiotherapy, especially intensity modified con-
formal radiotherapy, is the major therapeutic approach
for NPC [2]. Prognostic factors for nasopharyngeal can-
cer have been well-documented by several groups. T/N
and clinical stage, chemotherapy, radiation interruptions
and hemoglobin level are considered important prognos-
tic factors for NPC patients [3]. In the current study,
we include tumor volume as a candidate factor for
predicting treatment outcome of NPC treated in our
hospital. It was first proposed by Fletcher that tumor
volume might indicate the number of tumor clonogens
that should be removed [4]. The volume of the primary
tumor varies in the T classification, which suggests a
possible effect of tumor volume on survival after radio-
therapy. Indeed, tumor volume is included in the staging
systems of many types of tumors to predict prognosis.
For example, primary tumor volume is considered in the
lung cancer staging system. Larger lung tumor volume
might indicate poorer survival rates [5]. The Inter-
national Union Against Cancer (UICC) and the American
Joint Committee of Cancer (AJCC) staging systems are
widely used for NPC patients. Anatomic location of the
lesion and cranial nerve involvement are the critical sta-
ging factors in this system. However, discussions on the
prognostic and staging value of primary tumor and nodal
volume in NPC are notably limited, which warranted the
current study. Most studies used CT images to delineate
and measure the primary tumor and nodal volume. In the
current study, we used MRI to accurately evaluate the in-
vasion of the carcinoma. The tumor volumes derived from
MRI registration, as well as other important clinical pa-




From October 2003 to October 2005, a total of 447 NPC
patients treated with IMRT in the Sichuan Cancer Hos-
pital were retrospectively analyzed. The study was ap-
proved by the ethics committee of Sichuan Cancer
Hospital. Sixteen patients were excluded because of dis-
tant metastases at the time of initial diagnosis. Among
the remaining 431 patients, who were stage I-IVa+b,
only 386 patients received a MRI of the head and neck
at beginning of treatment. Ultimately, 363 cases had
complete medical information and entered the retro-
spective analysis. All patients received complete physical
examinations, endoscopy, CT and MRI of the head andneck, chest radiography, bone emission computed tom-
ography and dental assessments before treatment. They
received the nasopharyngeal neoplasm biopsy to con-
firm the NPC diagnosis pathologically. They were
staged according to the UICC 2002 staging system. The
characteristics and distribution of the patients are listed
in Table 1.
Volume measurement
All patients were placed in the supine position on a
Medtec positioning system with their head, neck and
shoulders fixed and a 2.0 cm cork in their mouth. Each
patient underwent a localized, contrast-enhanced CT
scan, with the cranial vertex as the upper limit and 2 cm
below the inferior margin of the clavicle head as the
Table 2 Univariate prognostic analysis of 363 NPC
patients for T stage and N stage
Prognostic factors LC RC DMFS OS
% p % p % p % p
T stage 0.355 0.014 0.002
T1 93.7 84.8 90.1
T2 90.6 82.5 88.4
T3 85.6 68.6 78.3
T4 84.3 65.5 74.5
N stage 0.105 0.003 0.005
N0 92.5 83.7 90.0
N1 90.8 80.1 88.3
N2 86.6 70.9 80.1
N3 83.4 66.5 73.4
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(Magnetom Avanto, Siemens, Germany) with a standard
clinical imaging protocol. T1-weighted fast spin-echo
images in the axial planes and T2-weighted fast spin-
echo fat- suppressed images in the axial plane and cor-
onal planes were obtained before the injection of
contrast material. After intravenous administration ofFigure 1 Kaplan-Meier curves showing the 5-year LC rate in TV1, TV2
the groups (p<0.001). The statistical analyses between each pair of groups
p=0.000; TV2 vs. TV3, p=0.365; TV2 vs. TV4, p=0.000; and TV3 vs. TV4, p=0.00gadopentetate dimeglumine (Schering, Germany) at a
dose of 0.1 mmol per kilogram of body weight, axial and
sagittal T1-weighted fat-suppressed spin-echo sequences
were performed sequentially. The scanning layer was
3.0 mm, and the layer interval was 2.5 mm. Registration
of MRI with planning CT images was performed for all
patients for accurate delineation of tumor volumes and
critical structures. The primary nasopharyngeal tumor
and neck positive nodes were outlined based on CT and
MRI registration images. The retropharyngeal nodes
were included in the primary nasopharyngeal tumor.
Positive nodes in the neck were diagnosed according to
the UICC2002 staging system. All images were evaluated
by two head and neck clinicians. Radiotherapy planning
was designed and optimized using the CORVUS 3.4-4.2
inverse treatment planning system (Corvus, Nomos Cor-
poration, Sewickley, PA, USA). The volumes of primary
tumor and nodes were calculated by the summation-of
-area technique in the system, which multiplied the en-
tire areas by the image reconstruction interval.
Treatment
Radiotherapy
A full course of IMRT was used in all patients. According
to the definitions of the International Commission on, TV3 and TV4 groups. There was a significant difference between
were as follows: TV1 vs. TV2, p=0.512; TV1 vs. TV3, p=0.161; TV1 vs. TV4,
1.
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target volumes were outlined in each layer of the CT im-
ages on an IMRT workstation. The gross tumor target of
nasopharynx (GTVnx) and right/left lymph nodes
(GTVln-R/L) were outlined based on the borders of the
nasopharyngeal tumor and lymph nodes as shown by CT
and MRI. High risk clinical target volume (CTV1) in-
cludes the GTVnx with a 5 to 10 mm margin and high-
risk structures. A smaller margin was used for the gross
nasopharyngeal tumor where it was adjacent to critical
neurologic structures. Low risk clinical target volume
(CTV2) covered CTV1 and was designed for potentially
involved regions including the nasopharyngeal cavity,
maxillary sinus, pterygopalatine fossa, posterior ethmoid
sinus, parapharyngeal space, skull base, anterior third of
clivus, inferior sphenoid sinus and cavernous sinus et al.
CTVln covered lymphatic drainage regions (including the
bilateral retropharyngeal nodes at levels II, III and VA).
Radiotherapy planning was designed and optimized using
the CORVUS 3.4-4.2 inverse treatment planning system.
The prescribed doses of each target area were as follows:
66–76 Gy for GTVnx, 60–70 Gy for GTVlnR/L, 60–66
Gy for CTV1, 54–60 Gy for CTV2 and 50–54 Gy for
CTVln. Each was divided into 30–33 deliveries. The dose
limits for each normal organ were set according to theFigure 2 Kaplan-Meier curves showing the 5-year DMFS rate in TV1, T
the groups (p=0.001). The statistical analyses between each pair of groups
p=0.000; TV2 vs. TV3, p=0.802; TV2 vs. TV4, p=0.006; and TV3 vs. TV4, p=0.00Radiation Therapy Oncology Group protocol 0225
(RTOG0225). The prescribed dose encompassed at least
95% of the target volume, no greater than 1% of nasophar-
ynx gross target volume could receive ≤93% of the
prescribed dose and the maximum dose of the treatment
plan was inside the target volume. The IMRT plan was
implemented through dynamic intensity-modulated copla-
nar arc irradiation using a multileaf collimator (Nomos
mimic). All of the patients received radiation in the lymph
node drainage areas in the lower neck using 60Co split-
field techniques or 6 MV X-ray split-beam techniques
with a prescription dose of 46-50 Gy.
Chemotherapy
Of the 363 patients, 93 patients received radiotherapy
only, while 270 received IMRT combined with chemother-
apy. Among these 270 patients, 57 received neoadjuvant
and concurrent chemotherapy, 116 patients received con-
current chemotherapy, and the remaining 97 received
concurrent-adjuvant chemotherapy. The patients who re-
ceived neoadjuvant chemotherapy meant they received 2
to 3 cycles of cisplatin-based chemotherapy every 3 weeks
before radiation. After completion of radiation, 1 to 2
cycle of adjuvant chemotherapy was given to the patients
who had residual disease. The neoadjuvant and adjuvantV2, TV3 and TV4 groups. There was a significant difference between
were as follows: TV1 vs. TV2, p=0.216; TV1 vs. TV3, p=0.142; TV1 vs. TV4,
9.
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cisplatin 30 mg/m2 d1-3 or cisplatin 30 mg/m2 d1-3 +
5-Fu 750 mg/m2 d1-5. The concurrent chemotherapy
protocol was cisplatin 30 mg/m2 d1-3 every 3 weeks for 2
to 3 cycle.
Follow-up
After completion of radiation and chemotherapy, pa-
tients were followed-up every 3 months in the first year,
every 6 months in the second year and then every 12
months in the following 3 years. The follow-up period
started from the date of diagnosis and ended on either
the date of death or the date of the last follow-up. Local
failure was defined as the recurrence at the nasopharyn-
geal cavity. Regional failure was defined as the recur-
rence of regional lymph nodes. Metastases to any site
beyond the primary tumor and lymph nodes were de-
fined as distant failure.
Statistical analysis
Statistical analysis was carried out using SPSS software
(IBM company, version 19), and the survival rate was cal-
culated using the Kaplan-Meier method. The log-rank test
was used for univariate analyses of prognostic factors, and
the Cox proportional hazard model was used forFigure 3 Kaplan-Meier curves showing the 5-year OS rate in TV1, TV2
the groups (p=0.002). The statistical analyses between each pair of groups
p=0.001; TV2 vs. TV3, p=0.470; TV2 vs. TV4, p=0.005; and TV3 vs. TV4, p=0.01independent multivariate prognostic analyses. P < 0.05
was considered statistically significant.
Results
The volume statistics of primary tumor and nodes
The primary tumor and nodal volume were automatic-
ally measured by the CORVUS 3.4-4.2 inverse treatment
planning system in 363 NPC patients. The mean value
of primary tumor and nodal volume were 31.5 (range
1.8 ml-112.4 ml) and 9.7 (range 1.3-82.6 ml) respectively.
The mean value of primary tumor volume in T1, T2,
T3 and T4 groups was 12.1 ml, 21.5 ml, 31.6 ml and
56.4 ml. The range of primary tumor volume was 1.8-
20.6 ml in T1 group, 4.3-67.8 ml in T2 group, 8.6-89.8 ml
in T3 group, and 23.7-92.3 ml in T4 group. The patients
were respectively divided into subgroups based on their
primary tumor and nodal volume. The four subgroups for
primary tumor volume were TV1≤20 ml, 20 ml<TV2≤30 ml,
30<TV3≤40 ml and TV4>40 ml; the four subgroups for
primary nodal volume were NV1≤5 ml, 5 ml <NV2≤10 ml,
10 ml <NV3≤15 ml and NV4 >15 ml.
Treatment outcome
The median follow-up time was 63 months (range 9–82
months) for all patients. The 5-year LC, RC, DMFS and, TV3 and TV4 groups. There was a significant difference between
were as follows: TV1 vs. TV2, p=0.387; TV1 vs. TV3, p=0.150; TV1 vs. TV4,
9.
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ively. Forty-three cases experienced local failure, 43
cases had regional failure and 93 cases had distant me-
tastases. There were 82 deaths.
Univariate analysis
The UICC2002 staging system was used in all enrolled
patients. The univariate analysis results for T/N stage
are shown in Table 2. For the T stage, the 5-year LC rate
was not significantly different (p=0.355). The 5-year
DMFS and OS rate for T3/T4 groups were lower than
T1/T2 groups (DMFS: T1 vs. T2, p=0.392; T3 vs. T4,
p=0.861; T2 vs. T3, p=0.024. OS: T1 vs. T2, p=0.129; T3
vs. T4, p=0.684; T2 vs. T3, p=0.015). The 5-year RC rate
was not significantly different between N stages
(p=0.105). N3/4 groups had lower 5-year OS and DMFS
rate than N1/2 groups (DMFS: N1 vs. N2, p=0.592; N3
vs. N4, p=0.152; N2 vs. N3, p=0.019. OS: N1 vs. N2,
p=0.608; N3 vs. N4, p=0.537; N2 vs. N3, p=0.005).
Based on the subgroups of primary tumor and nodal
volume defined previously, the 5-year LC rate for TV1,
TV2, TV3 and TV4 were 98.5%, 96.9%, 91.4% and 90.5%
(p<0.001), respectively. The 5-year DMFS rate were
83.7%, 77.8%, 76.4% and 61.3%, respectively (p=0.001).
TV4 had significantly lower LC (Figure 1) and DMFSFigure 4 Kaplan-Meier curves showing the 5-year RC rate in NV1, NV2
the groups (p=0.002). The statistical analyses between each pair of groups
NV4, p=0.005; NV2 vs. NV3, p=0.004; NV2 vs. NV4, p=0.001; and NV3 vs. NV4(Figure 2) rate than the other three groups. As for the 5-
year OS rate, they were 83.7%, 77.8%, 76.4% and 61.3%
in the TV1, TV2, TV3 and TV4 groups (p=0.002), re-
spectively. The 5-year OS rate for TV3 and TV4 was sig-
nificantly lower than the other two groups ((Figure 3).
The 5-year RC rate for the NV1, NV2, NV3 and NV4
groups were 95.1%, 93.9%, 83.1% and 75.4% (p<0.001),
respectively. The 5-year DMFS rate for these groups
were 83.3%, 80.0%, 69.8% and 64.0%, respectively, and
the 5-year OS rate were 90.2%, 88.2%, 81.6% and 74.2%,
respectively (p<0.001; p<0.001). The 5-year RC (Figure 4),
DMFS (Figure 5) and OS (Figure 6) rate were signifi-
cantly lower in NV3 and NV4 groups when compared to
NV1 and NV2 groups.
Multivariate analysis
Primary tumor volume, N stage and chemotherapy were
independent prognostic factors in this study. TV>40 ml
was an adverse prognostic factor for the 5-year LRC rate
(Table 3). N stage (N2/N3) was an adverse prognostic
factor for the 5-year DMFS and OS rate (Tables 4, 5).
Chemotherapy improved both the 5-year DMFS (Table 4)
and OS (Table 5) rate. Primary nodal volume, T stage,
sex and year had no statistical significance in multivari-
ate analysis (Tables 3, 4, 5)., NV3 and NV4 groups. There was a significant difference between
were as follows: NV1 vs. NV2, p=0.750; NV1 vs. NV3, p=0.014; NV1 vs.
, p=0.439.
Figure 5 Kaplan-Meier curves showing the 5-year DMFS rate in NV1, PNV2, NV3 and NV4 groups. There was a significant difference
between the groups (p=0.01). The statistical analyses between each pair of groups were as follows: NV1 vs. NV2, p=0.435; NV1 vs. NV3, p=0.012;
NV1 vs. NV4, p=0.010; NV2 vs. NV3, p=0.027; NV2 vs. NV4, p=0.034; and NV3 vs. NV4, p=0.548.
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We evaluated the prognostic significance of the primary
and nodal tumor volume in NPC patients treated with
IMRT based on CT and MRI images. Univariate and
multivariate analysis showed that primary tumor volume
was a new prognostic factor for survival rate. A primary
tumor volume of 40 ml may be the cut-off value. N stage
and chemotherapy remain important prognostic factors
for the 5-year DMFS and OS rate. Primary nodal volume
could predict the prognosis in univariate analysis, but
had no statistical significance in multivariate analysis.
Our univariate analysis showed that a TV>40 ml and
NV≥10 ml indicated the worse 5-year LC, RC, DMFS
and OS rate. However, only a TV >40 ml was an inde-
pendent prognostic factor for the 5-year LRC rate
in multivariate analysis. Primary nodal volume had
no statistical effect on the 5-year LRC rate. Neither pri-
mary tumor volume nor primary nodal volume was sig-
nificantly different in terms of the 5-year DMFS or OS
rate. Chen [6] revealed that the 5-year local failure-free
rate (LFFR) for V1 (<15.65 ml), V2 (15.65-24.25 ml), V3
(24.25-50.55 ml) and V4 (>50.55 ml) were 96.2%, 93.3%,
88.2% and 77.3%, respectively, in 112 NPC patients
treated with IMRT. TV4 had a significantly lower LFFR
and OS rate than the others. Chua [7] analyzed theprognostic significance of the volume of the primary
tumor and lymph nodes in 290 NPC patients. The re-
sults showed that a large variation in tumor volume was
present in different T stages of nasopharyngeal carcin-
oma, and primary tumor volume (>60 ml) represented
an independent adverse prognostic factor for LC rate. A
large nodal tumor volume (>30 ml) was associated with
significantly higher distant failure and lower disease-
specific survival rate and was significantly different in
multivariate analysis. Kim [8] also showed that a large
primary tumor volume (>30 ml) was associated with a
significantly lower RC rate in 60 NPC patients. Add-
itionally, nodal volume (>5 ml) was associated with sig-
nificantly lower regional control and lower disease-
specific survival rate. However, these three studies all
used CT images to delineate tumor volume. In a recent
study, Sarisahin [9] delineated tumor volumes based on
both CT and MRI, and evaluated the prognosis of 56
NPC patients. The primary tumor volume (>60 ml) was
found to be significant predictor for LC, DFS and DMFS
in univariate analysis. Together with these previous stud-
ies, the findings in our study strongly support the prog-
nostic value of primary tumor volume in predicting the
5-year LRC rate for NPC. However, the best cut-off of
primary tumor volume remains to be determined. In our
Figure 6 Kaplan-Meier curves showing the 5-year OS rate in NV1, NV2, NV3 and NV4 groups. There was a significant difference between
the groups (p=0.014). The statistical analyses between each two groups were as follows: NV1 vs. NV2, p=0.687; NV1 vs. NV3, p=0.026; NV1 vs. NV4,
p=0.023; NV2 vs. NV3, p=0.023; NV2 vs. NV4, p=0.026; and NV3 vs. NV4, p=0.490.
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univariate analyses for predicting the 5-year LC rate, and
a PV of 40 ml may be the cut-off value. Also, the multi-
variate analysis comes to the same conclusion. More
high-quality studies are needed to confirm this. In
addition, our univariate analysis showed the primary
nodal volume could predict the 5-year RC, DMFS and
OS. But the multivariate analysis found no statistical
difference. Only limited number of studies [7,8,10]
discussed on the relationship between primary nodal
volume and prognosis, and the cut-off values were dif-
ferent among these studies. The variations could be
caused by different reference images used in target de-
lineation. Most studies used CT images to delineate theTable 3 Multivariate analysis predicting 5-year LRC rate
Prognostic factors Hazard ratio 95% CI P value
Sex 1.240 0.707-2.177 0.453
Year 1.104 0.699-1.743 0.671
TV 2.454 1.407-4.280 0.002
NV 1.074 0.632-1.826 0.793
T stage 1.175 0.711-1.942 0.528
N stage 1.231 0.774-1.956 0.380
Chemotherapy 1.366 0.833-2.240 0.216primary tumor, but we used both CT and MRI images to
acquire tumor volume, a more accurate method than
CT alone. Several studies showed MRI defined the ex-
tent of nasopharyngeal disease better than CT did by its
superior capability in demonstrating primary soft tissue
invasion and subtle intracranial invasion [11]. The regis-
tration of CT and MRI images may be essential in NPC
treatment planning, because the complementary infor-
mation contained in the two modalities could provide
more accurate target definition. In our present study, we
did not compare the difference between CT and MRI de-
fined target volumes, but several studies showed that CT
and MRI images might lead to different target volume in
head and neck carcinoma. For NPC, Emami [12] showedTable 4 Multivariate analysis predicting 5-year DMFS rate
Prognostic factors Hazard ratio 95% CI P value
Sex 1.116 0.680-1.832 0.665
Year 0.893 0.588-1.356 0.596
TV 1.549 0.928-2.584 0.094
NV 1.457 0.903-2.352 0.123
T stage 1.433 0.896-2.293 0.133
N stage 1.600 1.048-2.442 0.030
Chemotherapy 1.813 1.172-2.805 0.008
Table 5 Multivariate analysis predicting 5-year OS rate
Prognostic factors Hazard ratio 95% CI P value
Sex 1.360 0.772-2.396 0.288
Year 0.938 0.599-1.471 0.781
TV 1.393 0.802-2.417 0.239
NV 1.480 0.883-2.482 0.137
T stage 1.670 0.997-2.796 0.239
N stage 1.662 1.048-2.635 0.031
Chemotherapy 2.360 1.498-3.717 0.000
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CT. But Rasch [13] found CT displayed 30% larger vol-
umes than MRI in advanced head-and-neck cancer pa-
tients. In addition to different imaging modality, the
target volumes were also susceptible to interobserver
variations [14]. Different oncologists may perceive differ-
ent criteria in delineation. The interobserver variation
always existed in target delineation, but different modal-
ity might cause interobservier variation in different
degree. Chung [11] found MRI targets had smaller
interobserver differences. So, owing to the improved
visualization in MRI, it might be an important method
to decrease the interobserver difference in NPC patients
which was used in our study. Beyond that, there was still
no consensus in the method for measuring volume.
Diameter-based volume, summation of areas and a vol-
ume algorithm were all used in different studies. So, it
was still hard to evaluate the difference between MRI
and CT based target volume in NPC, further studies
were needed to resolve these issues.
In the univariate analysis of our study, T and N stage
had no significant effect on the 5-year LC and RC rate,
but they affected the 5-year DMFS and OS rate signifi-
cantly. In multivariate analysis, it was revealed that N
stage and chemotherapy were the important prognostic
factors for the 5-year DMFS and OS trate. However, T
stage was not predictive for these endpoints. This result
was consistent with two recent studies. Han [15]
reported that T stage was not an independent prognostic
factor for LC and OS in 305 patients with NPC treated
with IMRT. Bilgin [3] found that T and N stage had no
significant effect on LC or RC. N stage and response to
treatment were the most important independent predic-
tors of OS in their study. According to these findings,
we proposed that the current TNM staging system
should include the tumor volume as an important sta-
ging factor that could define the real and three-
dimensional tumor burden. A larger primary tumor and
nodal volume mean a heavier tumor load, usually
resulting in hypoxia, radiation resistance and poor rates
of tumor control. Given the fact that tumor volume may
have broad variation even in the same T classification, itis conceivable that in the current study, primary tumor
volume had more predictive power than the T stage for
LC. In our study, N stage remained important for
predicting DMFS and OS, but it was less effective in
predicting RC than primary nodal volume, although
none of these were statistically significant.
PET-CT has an advantage in indicating the biological
margins of tumors, which may have an important role in
defining tumor volume. The current study did not in-
clude PET-CT which warrants a future study on the
prognostic role of primary tumor volume based PET-CT
images for NPC patients. The cut-off value for tumor
and nodal volume was another issue that needs further
discussion. This finding might be explained by inter-
observer and inter-institution variation in target delinea-
tion and volume calculation, which may influence the
predictive value of primary tumor and nodal volume.
The specific correlation between the tumor volume and
treatment strategy was not analyzed in this study. Chen
[16] considered that large primary tumor volume would
require more aggressive treatment. Lee [17] reported
that OS was better after ≥4 cycles of chemotherapy than
after fewer than 4 cycles for a large primary tumor and
retropharyngeal lymph node volume (≥13 ml). A large
randomized controlled study is needed to address
whether intensive chemotherapy would alter the progno-
sis of NPC with large primary tumor volume.
Conclusions
Based on survival analysis of 365 cases of NPC consecu-
tively treated in our center from 2003–2005, we found
that primary tumor volume could be used as a prognos-
tic factor for NPC. This factor was more effective than T
classification in predicting LC. Primary nodal volume
had greater potential to predict RC than N stage but was
not statistically significant. We suggest that primary
tumor volume should be included in NPC staging and
considered an important factor for predicting treatment
outcomes.
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